Dapagliflozin in Active Lupus Nephritis

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Brigham and Women's Hospital
Study ID
NCT07323524
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Lupus Nephritis (LN)

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Lupus nephritis is a chronic and life-threatening autoimmune cause of kidney disease that predominately impacts young people and can lead to kidney failure. Sodium-glucose co-transporter-2 inhibitors, including dapagliflozin, are known to improve outcomes for people with other causes of chronic kidney disease. This pilot and feasibility randomized clinical trial will test the use of dapagliflozin versus placebo in addition to standard of care treatment for patients with early and active lupus nephritis, a group who has not been included in past trials.

Key Dates

Start date
May 19, 2026
Status verified
May 2026
Primary completion
Jul 31, 2029
Completion
Jan 31, 2030

Study Design

Enrollment
33 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Dapagliflozin 10 mg daily
    Subjects will receive masked dapagliflozin 10 mg daily for 12 weeks
  • Placebo Comparator: Matching placebo pill daily
    Subjects will receive a matching placebo pill to take daily for 12 weeks

Primary Outcome Measure

Proportion of eligible enrolled [ Time Frame: 3 years ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Brigham and Women's HospitalBostonMassachusetts02115
Karen H. Costenbader, MD, MPH
[email protected]
617-732-6088
Massachusetts General HospitalBostonMassachusetts02114
April M. Jorge, MD
[email protected]
617-643-9624

Find similar trials in Boston, MA

By research site
Brigham and Women's Hospital· Boston, MAMassachusetts General Hospital· Boston, MA

Related Studies